Coreline Soft’s AI-powered Lung Cancer Screening Software Added to Bayer’s Medical AI Platform
South Korean company Coreline Soft has recently announced that its AI-powered lung cancer screening analysis software, AVIEW LCS, has been included in the medical AI platform of global pharmaceutical firm Bayer. This software is now available on Bayer’s vendor-neutral, cloud-based marketplace, Calantic, alongside similar solutions from companies like Lunit and Us2.ai.
Calantic is a Software as a Service (SaaS) platform that enables healthcare providers to access and utilize multiple AI applications from different providers and manage contracts in a single location.
Importance of Coreline Soft’s Inclusion in Calantic
This integration into Calantic allows Coreline Soft to offer its lung cancer imaging AI software to governments and local hospitals across Europe. The company has strategic plans to expand its presence in Germany through its partnership with Bayer, including an exclusive supply deal with the German government for its lung cancer screening trial, HANSE. Coreline Soft is also in discussions with various hospitals across Europe for additional supply agreements.
Industry Trends and Expansion Strategies
Coreline Soft, which went public in 2023, has been actively expanding its reach globally. In Europe, the company has secured supply contracts with hospitals in France, Spain, Switzerland, and Austria. This year, Coreline Soft has also entered the Chinese and Australian markets through local partnerships.
Additionally, Coreline Soft partnered with Vuno, another Korean medical imaging AI company, to enter the Japanese market by selling its AI-powered lung disease diagnosis support software and business. In 2023, Coreline Soft obtained its 10th and 11th 510(k) clearances from the FDA for its AI-powered diagnostic support solution for coronary artery disease and its enhanced medical imaging analysis platform, AVIEW 2.0, respectively.
